Stockholm - Delayed Quote SEK

NextCell Pharma AB (NXTCL.ST)

Compare
2.6600 +0.0800 (+3.10%)
At close: December 20 at 5:29:40 PM GMT+1
Loading Chart for NXTCL.ST
DELL
  • Previous Close 2.5800
  • Open 2.5800
  • Bid 2.5600 x --
  • Ask 2.6600 x --
  • Day's Range 2.5400 - 2.8000
  • 52 Week Range 0.9953 - 4.0300
  • Volume 496,281
  • Avg. Volume 297,856
  • Market Cap (intraday) 194.423M
  • Beta (5Y Monthly) 0.71
  • PE Ratio (TTM) --
  • EPS (TTM) -0.5700
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden.

www.nextcellpharma.com

--

Full Time Employees

August 31

Fiscal Year Ends

Recent News: NXTCL.ST

View More

Performance Overview: NXTCL.ST

Trailing total returns as of 12/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NXTCL.ST
1.14%
OMX Stockholm 30 Index
3.19%

1-Year Return

NXTCL.ST
6.34%
OMX Stockholm 30 Index
3.78%

3-Year Return

NXTCL.ST
66.87%
OMX Stockholm 30 Index
7.32%

5-Year Return

NXTCL.ST
40.59%
OMX Stockholm 30 Index
38.77%

Compare To: NXTCL.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NXTCL.ST

View More

Valuation Measures

Annual
As of 12/20/2024
  • Market Cap

    194.42M

  • Enterprise Value

    147.63M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    18.23

  • Price/Book (mrq)

    2.88

  • Enterprise Value/Revenue

    13.84

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -31.72%

  • Return on Equity (ttm)

    -58.55%

  • Revenue (ttm)

    11.28M

  • Net Income Avi to Common (ttm)

    -41.96M

  • Diluted EPS (ttm)

    -0.5700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    46.79M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -22.93M

Research Analysis: NXTCL.ST

View More

Company Insights: NXTCL.ST

Research Reports: NXTCL.ST

View More

People Also Watch